23 results about "Airway hyperresponsiveness" patented technology

The invention discloses an application of glucopyranose galactooligosacharide in preparation of a medicine for treating and / or preventing allergic asthma. The invention finds that the glucopyranose galactooligosaccharide can obviously relieve airway inflammatory reaction of an allergen-induced allergic asthma model, including reducing airway inflammatory factor level, improving airway hyperreactivity and reducing lung inflammatory cell infiltration, and has no abnormal influence on blood routine and main organ functions; the composition has the advantages of small drug application dosage, low pharmaceutical cost, high safety, remarkable drug effect and the like, and has a wide application prospect.

The invention relates to the technical field of probiotics, in particular to an application of a probiotic (Bifidobacterium longum) in allergic asthma (preventing, relieving or treating allergic asthma). The invention relates to an application of probiotics in allergic asthma, in particular to an application of the probiotics in inhibiting a PI3K / AKT / NF-kappa B signal channel. According to the probiotics disclosed by the invention, activation of a PI3K / AKT / NF-kappa B signal channel is specifically inhibited, immune imbalance is regulated and controlled from the source, and Th2 type immune response is effectively inhibited. Specifically, the total IgE level in serum and the expression of Th2 type cytokines such as IL-4, IL-5 and IL-13 are remarkably reduced, the inflammatory response of the airway mainly caused by eosinophilic granulocyte infiltration is relieved, and the airway high reactivity and airway remodeling are effectively improved. The invention provides a novel intervention strategy which is clear in mechanism, high in safety and capable of treating both symptoms and root causes according to the intestine-lung axis theory, and has a wide application prospect in the aspect of treating allergic asthma.

The invention relates to the technical field of immunology and biomedicine, in particular to application of CD23 as a target spot to preparation of a medicine for treating IL-17 mediated diseases. By enhancing the expression or function of CD23, an IL-7R alpha-mediated mTORC2-AKT signal channel is activated, the expression of Bcl-2 is promoted, and the apoptosis of NKT17 cells is inhibited, so that the steady state and function of the NKT17 cells are maintained. Experimental results show that the deletion of CD23 causes the reduction of NKT17 cells, the expression of p-AKT (Ser473) and Bcl-2 is reduced, and the signal activity can be recovered by the supplementation of exogenous IL-7. The dependency of the signal path is further verified by using an mTORC2 inhibitor. An airway hyperreactivity model experiment shows that the lung airway hyperreactivity of a CD23-deficient mouse can be reduced, the IL-17 level is reduced, and the inflammatory response is relieved.

The utility model discloses an improved respirator mask, relates to the field of respirator masks, and provides an improved respirator mask which comprises a mask body and is characterized in that an adjusting structure capable of adjusting according to face conditions of different patients is arranged on the mask body; and an extension part which is conveniently attached to the lower jaws of different patients is arranged below the mask body. According to the utility model, adaptive adjustment can be carried out according to face conditions of different patients, especially for some people with retrograde or small mandible and edentulous old people with rhinitis or high airway reactivity, the device can be attached to the face of the patient, leakage of inhaled medicaments and oxygen cannot be caused, waste of medicaments and oxygen cannot be caused, and the device is suitable for popularization and application. Meanwhile, the treatment and oxygen uptake effects of the patient are better.

The application belongs to the technical field of biological medicine, and particularly relates to application of CDC37 protein in preparation of Treg cell dysregulation disease treatment product. The application obtains a CDC37 protein with immunoregulatory function and high expression through mass spectrum analysis and bioinformatics analysis on proteins of lung stage child worms of Japanese blood flukes. The amino acid sequence of the CDC37 protein is shown as SEQ ID NO. 1, and the nucleotide sequence of the gene coding the CDC37 protein is shown as SEQ ID NO. 2. Experimental results show that the CDC37 protein can realize the effect of non-hormone-dependent long-acting relief of Treg cell dysregulation diseases by inducing Treg cell expansion, inhibiting Th2 response and reducing airway hyperresponsiveness, and can be used for preparation of Treg cell dysregulation disease treatment product.

The invention belongs to the technical field of biological medicines, and discloses application of AC1903 in preparation of drugs for treating and preventing neutrophil asthma. The invention provides the application of the TRPC5 inhibitor (especially AC1903 or pharmaceutically acceptable salt thereof) in preparation of drugs for preventing and / or treating asthma (especially neutrophil asthma) for the first time. Experiments prove that by intraperitoneal injection of AC1903, the wheezing symptom of a TDI asthma mouse can be remarkably relieved, the airway hyperreactivity, the airway surrounding inflammation level, the total number of inflammatory cells in the airway and the neutrophil count of the TDI asthma mouse are relieved, and secretion of type-2 cytokines and type-17 cytokines of alveolar lavage fluid of the asthma mouse is inhibited. The traditional Chinese medicine composition has a good treatment effect on asthma and has no obvious toxic or side effect.

Disclosed in the present invention is a fusion protein inhalant for treating respiratory allergic diseases. The present invention provides a use of a fusion protein in preparation of a drug for treating respiratory allergic diseases. The fusion protein has an amino acid sequence as shown in SEQ ID NO: 3. The fusion protein inhalant provided by the present invention can effectively reduce inflammatory cell infiltration in lung tissue and around bronchi, and reduce airway hyperresponsiveness.

The invention discloses a traditional Chinese medicine composition with an effect of treating children asthma migration and delay and a preparation method thereof. Through a large number of clinical practices, the traditional Chinese medicine composition is prepared from raw materials including raw radix astragali, radix ephedrae, fructus perillae, radix paeoniae rubra, rhizoma belamcandae, bulbus lilii, honey-fried radix stemonae, flos magnoliae, herba schizonepetae and fructus mume. The traditional Chinese medicine composition has the effects of tonifying qi, strengthening superficies, depressing qi, reducing phlegm, dispelling wind and preventing asthma, and is used for treating qi deficiency and phlegm lingering in asthma of children. Clinical verifications prove that the traditional Chinese medicine composition can obviously improve the clinical symptoms of asthma, wheeze, chest distress, cough and the like of asthma migrant and delay children, and reduce the incidence frequency. Animal experiment research shows that the traditional Chinese medicine composition can effectively improve lung functions of asthma migrant and delay model mice, reduce airway resistance and relieve airway hyperresponse; the traditional Chinese medicine composition can relieve inflammation, reduce airway mucus hypersecretion, reduce airway collagen deposition, delay airway remodeling and improve anaphylaxis. The traditional Chinese medicine composition can be used for filling the market blank of treating children asthma migration and delay based on the theories of qi regulation, qi depressing and wind phlegm, and has a very good development prospect.

The present invention relates to the treatment of inflammation. Here, the inventors generated a mouse model able to trace the expression of MrgprE and to interrogate its function, in vivo. They identified the cells expressing MrgprE notably among leukocytes. The MrgprEMut mice do not present any abnormality especially in the immune and peripheral nervous systems. Interestingly, the ablation of MrgprE expression decrease significantly asthma associated airway hyperresponsiveness and inflammation; symptoms that are restored when MrgprE is expressed by Nav1.8+ sensory fibers. In the context of asthma, an inhibitor of MrgprE could have a dual mode of action preventing both airway hyperresponsiveness and inflammation. Thus, the present invention relates to a MRGPRE binding agent for use in the treatment of inflammatory disorders in a subject in need thereof.

The invention belongs to the technical field of biological medicine, and particularly relates to application of CDC37 protein in preparation of a product for treating Treg cell dysfunctional diseases, the CDC37 protein with an immune regulation function and high expression is obtained by performing mass spectrometry and biosignal analysis on protein of schistosoma japonicum lung-stage juvenile worms, the amino acid sequence of the CDC37 protein is shown as SEQ ID NO.1, and the CDC37 protein can be applied to preparation of a product for treating Treg cell dysfunctional diseases. The nucleotide sequence of the gene for coding the CDC37 protein is as shown in SEQ ID NO. 2. Experimental results show that CDC37 protein can achieve the effect of non-hormone-dependent long-acting alleviation of the Treg cell dysregulated diseases by inducing Treg cell amplification, inhibiting Th2 reaction and reducing airway hyperreactivity, and can be used for preparing a product for treating the Treg cell dysregulated diseases.

Bronchial remodelling is a prominent feature of severe asthma and a potential therapeutic target. Some data indicate that Th17 cytokines in particular IL-22 may be involved in remodelling processes in vitro, and in skin remodelling in vivo. The aim of the inventors was to evaluate if Th17 cytokines are involved in bronchial remodelling in a severe model of allergic asthma, and if this was amplified by co-sensitization with NOD2 agonist, MDP, a ligand favouring Th17 polarization. Dog allergen challenge led to a predominant neutrophilic infiltration in Broncho-alveolar lavage (BAL), increased dog-specific IgE production, airways hyperresponsiveness, and increased Th17 cytokine production. Increased bronchial remodeling was observed in dog allergen challenged mice compared to control. IL-22 deficiency decreased airway hyperresponsiveness, bronchial mucus production as well as peribronchial collagen deposition, in the allergen-challenged group. Th17 cytokines in particular IL-22 participate in the bronchial remodeling in a chronic model of neutrophilic asthma, and may represent a therapeutic target in severe asthma.

The invention relates to the technical field of animal model construction, in particular to an animal model for inducing non-allergic rhinitis by temperature change, a method for constructing the animal model and a new scheme for researching an inflammation mechanism of the animal model, and particularly relates to a method for constructing the animal model for inducing non-allergic rhinitis by temperature change. The invention intends to re-cognize upper airway hyperresponsiveness diseases from the perspective of peripheral neuroimmunology, explore a new modeling method of NAR mice, and aims to induce non-allergic rhinitis by using temperature change, deepen cognition of NAR specific pathogenesis, study a specific mechanism of neuropeptide rise, strive to achieve the purpose of diagnosing and treating rhinitis according to the principle of precision medicine, and provide a new model for the NAR mice. An animal model and an animal experiment basis are provided for new clinical treatment in the future, and the method comprises a grouping step, an experiment step and an animal model evaluation setting step.

The invention discloses an inherited cough and asthma relieving compound medicine and a preparation method thereof. The medicine is prepared into various dosage forms such as granules, tablets and the like from 14 traditional Chinese medicines such as honey-fried ephedra, semen armeniacae amarae, lumbricus and the like through the processes of superfine grinding, gradient decoction, low-temperature drying and the like. The innovation points are as follows: (1) ephedra-earthworm synergistically relieve spasm, stiff silkworm-schisandra chinensis jointly regulate and control a calcium ion channel, and rapid cough relieving and long-acting asthma relieving are realized; (2) gradient decoction is combined with an inclusion technology, so that the dissolution rate of ephedrine is increased by 42%, and the retention rate of glycyrrhizic acid is greater than or equal to 78%; (3) an IL-6 / TNF-alpha inflammation pathway is inhibited at multiple targets, and the airway hyperreactivity is reduced; and (4) the granule D90 is less than or equal to 150 microns, the water content is less than or equal to 5%, and the dissolution rate reaches 90% or above. Clinical tests show that the total effective rate is 91.7%, the FEV1 improvement rate is improved by 41.7% compared with that of a single-formula control group, and the hormone dosage can be reduced by 30%. The preparation has the advantages of traditional cough treatment experience and modern pharmaceutical technology, and provides a safe and effective new choice for treatment of CVA.

The invention belongs to the field of biomedicine, and relates to an establishment method and application of an allergic asthma susceptible mouse model. According to the method, a filial generation allergic asthma susceptible animal model is constructed through exposure of amoxicillin in a perinatal period, intragastric administration is performed on a female mouse from the 13th day of pregnancy to the 7th day of postpartum in an experiment, and a key window in the perinatal period is covered. And the filial generation is sensitized and excited by ovalbumin (OVA) to establish a standardized asthma model. It is found that exposure of amoxicillin in the perigenic period significantly reduces the richness and diversity of filial generation flora and inhibits taurine metabolism, resulting in significant increase of airway hyperreactivity and eosinophilic granulocytes in alveolar lavage fluid. The cycle of the model is shortened to 28 days, and by combining metabolome and 16S sequencing data, a new mechanism that antibiotics influence asthma susceptibility through a flora-metabolite axis is disclosed, and an experimental basis and a quantitative strategy are provided for clinical intervention.

The invention discloses application of human metapneumovirus in preparation of a medicine for treating asthma, and belongs to the technical field of asthma medicines. The human metapneumovirus is used in the medicine for treating asthma, can relieve airway hyperresponsiveness of an asthma patient, reduce expression of MUC5AC, IL-4 and p-STAT6 proteins of the asthma patient, reduce the total cell number, eosinophilic granulocyte number and neutrophil number in BALF, and can effectively treat asthma and relieve asthma symptoms.

The invention belongs to the field of biological medicines and plant preparations, and discloses a chamomile extract compound preparation for treating asthma and an application of the chamomile extract compound preparation. The preparation consists of a German chamomile extract (containing alpha-bisabolol), a hedera helix extract (containing alpha-hederin), EDTA-2Na (Ethylene Diamine Tetraacetic Acid), rosmarinic acid and pharmaceutic adjuvants, and can be prepared into aerosol. The preparation method comprises the following steps: extracting active ingredients of chamomile and hedera helix through supercritical CO2, and performing high-pressure homogenization (20,000 psi) to form a nano suspension with D90 less than or equal to 5 microns (NGI + verifies that FPF is less than 3 microns and the proportion is greater than or equal to 70%). The compound inhibits an NF-kB / STAT3 inflammatory pathway and PDE4 activity through a multi-target synergistic effect, and significantly improves airway hyperreactivity. In addition, the invention further provides an aerosol spray prepared from the compound, and the aerosol spray is suitable for long-term control and acute attack treatment of children asthma.

Disclosed in the present invention is a fusion protein inhalant for treating respiratory allergic diseases. The present invention provides a use of a fusion protein in preparation of a drug for treating respiratory allergic diseases. The fusion protein has an amino acid sequence as shown in SEQ ID NO: 3. The fusion protein inhalant provided by the present invention can effectively reduce inflammatory cell infiltration in lung tissue and around bronchi, and reduce airway hyperresponsiveness.

This invention discloses a traditional Chinese medicine composition containing donkey-hide gelatin and its application in the preparation of drugs or foods for the prevention and / or treatment of chronic lung diseases, belonging to the field of traditional Chinese medicine technology. This invention provides a traditional Chinese medicine composition containing donkey-hide gelatin, which is a compound formula containing donkey-hide gelatin. Donkey-hide gelatin is the principal ingredient, burdock seed and clam shell are the assistant ingredients, apricot kernel is the adjuvant ingredient, and glutinous rice and prepared licorice root are the guiding ingredients. Through this combination, a multi-target synergistic regulatory mechanism is achieved. By synergistically inhibiting the PI3K / Akt signaling pathway through multiple targets and pathways, it significantly reduces airway inflammation, airway hyperresponsiveness, and serum IgE levels in the model. The traditional Chinese medicine composition provided by this invention has a simple and easy preparation process, employing a combined technique of water extraction and volatile oil extraction to maximize the retention of active ingredients. The traditional Chinese medicine composition provided by this invention solves the problems of single target or unclear mechanism in existing technologies, and has broad application prospects in the use of traditional Chinese medicine compositions containing donkey-hide gelatin in the prevention and / or treatment of chronic lung diseases.

The application relates to a triterpenoid compound A2 extracted from oriental alisma, and a preparation method thereof. The preparation method is as follows: oriental alisma is dried and crushed, soaked with acetone at room temperature, broken and extracted, filtered, and the filter liquor is combined and concentrated under reduced pressure to obtain an extract; the extract is extracted with equal amounts of petroleum ether, dichloromethane, ethyl acetate and n-butanol in sequence, concentrated and dried to obtain a petroleum ether part, a dichloromethane part, an ethyl acetate part, an n-butanol part and a water part; the dichloromethane part is dissolved in methanol, mixed with silica gel, loaded on a column and eluted four times to obtain a target flow fraction; the target flow fraction is loaded on a chromatographic column, the flow fraction in the retention time is collected, concentrated and dried, and the triterpenoid compound A2 is obtained. The raw material is rich, the unique preparation method is adopted, the compound A2 can improve airway inflammation and airway hyperresponsiveness of OVA-induced allergic asthma, can be used for preparing a medicine for treating allergic asthma, expands the medicinal value and economic value of the oriental alisma, and has great economic and social benefits.

This invention discloses the application of glycyrrhizin in the preparation of drugs for the treatment or prevention of chronic obstructive pulmonary disease (COPD), relating to the field of biomedical technology. Specifically, this invention discloses the application of glycyrrhizin or its pharmaceutically acceptable salts in the preparation of drugs for the treatment and / or prevention of COPD. Through drug screening and in vitro and in vivo experiments, this invention is the first to demonstrate that glycyrrhizin can not only inhibit inflammation, but also has a better effect than glycyrrhizic acid, a natural product derived from licorice. Furthermore, this invention functionally demonstrates that glycyrrhizin can significantly improve the decline in lung function and reduce airway hyperresponsiveness in COPD model animals; pathologically, it confirms that it can effectively reduce pulmonary inflammatory infiltration and tissue damage; and molecularly, it demonstrates that glycyrrhizin has the effect of inhibiting the expression of inflammatory factors, and its effect is better than that of the positive control drug dexamethasone, showing great promise for its application in the treatment of COPD.

The invention discloses application of SGX942 in preparation of a medicine for treating asthma, the asthma is allergic asthma induced by dual effects of PM2.5 and dermatophagoides pteronyssinus, the invention further discloses the medicine for treating asthma, and the SGX942 is taken as an active ingredient. The invention discloses a new function of the SGX942, and the SGX942 can reduce airway hyperresponsiveness of asthma mice, reduce lung inflammation and airway mucus secretion, and relieve asthma-related pathological changes by inhibiting airway cell mitochondrial autophagy.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and particularly to the application of TCM compositions in the preparation of drugs for the prevention and treatment of asthma. The TCM composition includes Astragalus membranaceus, Eupolyphaga sinensis, Morus alba root bark, Fritillaria cirrhosa, Perilla frutescens seed, Lepidium apetalum seed, Prunus armeniaca seed, Pheretima aspergillum, Ephedra sinica, and Clematis chinensis. Experiments show that the TCM composition provided by this invention can effectively improve airway hyperresponsiveness, reduce lung resistance, and enhance dynamic lung compliance in asthma model animals. Simultaneously, it can significantly reduce the content of pro-inflammatory factors IL-4 and IL-13 in the bronchoalveolar lavage fluid of asthma models, alleviate airway inflammation, and relieve asthma pathological symptoms. It can stably exert its effect in preventing and treating asthma, and its efficacy is stable and its safety is good. It can be further developed into a drug for the prevention and treatment of asthma and has good clinical application prospects.

The invention discloses a preparation method and application of a meroterpenoid compound. According to the preparation method of the meroterpenoids, the meroterpenoids CBCO are extracted and separated from the overground part of rhododendron capitatum for the first time, the preparation method has the advantages that the separation method is simple, convenient and rapid, and the separated compound is high in purity, a novel preparation method is provided for CBCO, and the preparation method has important practical significance and wide market prospects. The meroterpenoid is applied to preparation of the medicine for preventing / treating asthma, CBCO is applied to prevention and treatment of bronchial asthma, and a new medicine choice is brought to asthma patients. Experimental results show that the CBCO can obviously relieve airway inflammation and airway hyperresponsiveness and inhibit secretion of related inflammatory factors such as IL-4, IL-5 and IL-13, has the effect of reducing inflammatory cells around the airway and the blood vessel, and achieves the effect of treating the asthma.